NASDAQ:SUPN - Supernus Pharmaceuticals Stock Price, Forecast & News

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SUPN shares have increased by 9.0% and is now trading at $17.60. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Supernus Pharmaceuticals.

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Supernus Pharmaceuticals.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) posted its earnings results on Tuesday, February, 25th. The specialty pharmaceutical company reported $0.62 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.05. The specialty pharmaceutical company earned $100.45 million during the quarter, compared to analyst estimates of $107.27 million. Supernus Pharmaceuticals had a net margin of 28.78% and a return on equity of 20.98%. View Supernus Pharmaceuticals' earnings history.

Supernus Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360-390 million, compared to the consensus revenue estimate of $407.73 million.

6 Wall Street analysts have issued twelve-month price objectives for Supernus Pharmaceuticals' stock. Their forecasts range from $23.00 to $63.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $43.80 in the next twelve months. This suggests a possible upside of 148.9% from the stock's current price. View analysts' price targets for Supernus Pharmaceuticals.

Headlines about SUPN stock have trended very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Supernus Pharmaceuticals earned a daily sentiment score of 3.2 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutSupernus Pharmaceuticals.

Supernus Pharmaceuticals saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 5,581,700 shares, a decline of 10.4% from the February 27th total of 6,230,000 shares. Based on an average daily trading volume, of 653,000 shares, the short-interest ratio is presently 8.5 days. Approximately 11.0% of the company's shares are sold short. View Supernus Pharmaceuticals' Current Options Chain.

Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Exelixis (EXEL), Netflix (NFLX), Cara Therapeutics (CARA), Corcept Therapeutics (CORT) and Pfizer (PFE).

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SUPN stock can currently be purchased for approximately $17.60.

Supernus Pharmaceuticals has a market capitalization of $924.53 million and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe. View additional information about Supernus Pharmaceuticals.

The official website for Supernus Pharmaceuticals is http://www.supernus.com/.

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]